drugset
drugset / Trial / NCT00209924

A Study of Gaboxadol in Primary Insomnia

NCT00209924 ↗

Phase 3 Completed 505 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.

Timeline

Start
2004-04
Primary completion
—
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Gaboxadol Unknown — —

Indications

insomnia